$GOSS
Gossamer Bio, Inc.

2021 Q2 Form 10-Q Financial Statement

#000172811721000087 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.26M $11.66M
YoY Change -3.4% 20.58%
% of Gross Profit
Research & Development $44.32M $38.68M
YoY Change 14.56% 8.43%
% of Gross Profit
Depreciation & Amortization $422.0K $350.0K
YoY Change 20.57% 75.0%
% of Gross Profit
Operating Expenses $55.60M $65.34M
YoY Change -14.91% 40.97%
Operating Profit -$55.60M -$65.34M
YoY Change -14.91% 40.97%
Interest Expense $4.834M $2.491M
YoY Change 94.06%
% of Operating Profit
Other Income/Expense, Net -$4.236M -$1.531M
YoY Change 176.68% -182.71%
Pretax Income -$59.83M -$66.87M
YoY Change -10.52% 50.27%
Income Tax
% Of Pretax Income
Net Earnings -$59.83M -$66.87M
YoY Change -10.52% 50.28%
Net Earnings / Revenue
Basic Earnings Per Share -$0.80 -$1.00
Diluted Earnings Per Share -$0.80 -$1.00
COMMON SHARES
Basic Shares Outstanding 74.67M shares 66.60M shares
Diluted Shares Outstanding 74.67M shares 66.60M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $405.9M $600.4M
YoY Change -32.39% 29.4%
Cash & Equivalents $342.5M $486.1M
Short-Term Investments $63.47M $114.3M
Other Short-Term Assets $11.07M $8.000M
YoY Change 38.35% -68.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $417.0M $608.4M
YoY Change -31.46% 24.27%
LONG-TERM ASSETS
Property, Plant & Equipment $5.632M $5.757M
YoY Change -2.17% 19.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.070M $600.0K
YoY Change 78.33% -56.11%
Total Long-Term Assets $15.52M $16.70M
YoY Change -7.05% -5.05%
TOTAL ASSETS
Total Short-Term Assets $417.0M $608.4M
Total Long-Term Assets $15.52M $16.70M
Total Assets $432.5M $625.1M
YoY Change -30.81% 23.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $895.0K $200.0K
YoY Change 347.5% -93.4%
Accrued Expenses $15.88M $27.30M
YoY Change -41.83% 196.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $29.98M $27.50M
YoY Change 9.03% -0.04%
LONG-TERM LIABILITIES
Long-Term Debt $28.91M $28.64M
YoY Change 0.94% 1.26%
Other Long-Term Liabilities $6.165M $7.900M
YoY Change -21.96% -20.2%
Total Long-Term Liabilities $28.91M $28.64M
YoY Change 0.94% 1.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.98M $27.50M
Total Long-Term Liabilities $28.91M $28.64M
Total Liabilities $211.8M $204.8M
YoY Change 3.45% 211.5%
SHAREHOLDERS EQUITY
Retained Earnings -$695.0M
YoY Change
Common Stock $915.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $220.7M $420.3M
YoY Change
Total Liabilities & Shareholders Equity $432.5M $625.1M
YoY Change -30.81% 23.25%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$59.83M -$66.87M
YoY Change -10.52% 50.28%
Depreciation, Depletion And Amortization $422.0K $350.0K
YoY Change 20.57% 75.0%
Cash From Operating Activities -$47.45M -$42.39M
YoY Change 11.93% 15.16%
INVESTING ACTIVITIES
Capital Expenditures -$140.0K -$440.0K
YoY Change -68.18% -68.12%
Acquisitions
YoY Change
Other Investing Activities -$49.94M $106.7M
YoY Change -146.81% -953.52%
Cash From Investing Activities -$50.08M $106.2M
YoY Change -147.14% -864.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $117.1M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 275.0K 310.8M
YoY Change -99.91% 996.4%
NET CHANGE
Cash From Operating Activities -47.45M -42.39M
Cash From Investing Activities -50.08M 106.2M
Cash From Financing Activities 275.0K 310.8M
Net Change In Cash -97.25M 374.7M
YoY Change -125.96% -1776.42%
FREE CASH FLOW
Cash From Operating Activities -$47.45M -$42.39M
Capital Expenditures -$140.0K -$440.0K
Free Cash Flow -$47.31M -$41.95M
YoY Change 12.77% 18.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001728117
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38796
dei Entity Registrant Name
EntityRegistrantName
GOSSAMER BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5461709
dei Entity Address Address Line1
EntityAddressAddressLine1
3013 Science Park Road
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
684-1300
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
GOSS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
75993532 shares
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
342453000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
486055000 USD
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
63466000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
26573000 USD
CY2021Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
566000 USD
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
565000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10502000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9129000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
416987000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
522322000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5632000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5534000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8821000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10550000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1070000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1027000 USD
CY2021Q2 us-gaap Assets
Assets
432510000 USD
CY2020Q4 us-gaap Assets
Assets
539433000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
895000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7508000 USD
CY2021Q2 goss Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
13206000 USD
CY2020Q4 goss Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
10431000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15881000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20711000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
29982000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38650000 USD
CY2021Q2 goss Long Term Convertible Senior Notes
LongTermConvertibleSeniorNotes
146765000 USD
CY2020Q4 goss Long Term Convertible Senior Notes
LongTermConvertibleSeniorNotes
143642000 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28905000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28744000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6165000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7713000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
211817000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
218749000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
70000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
70000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
700000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
700000000 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75988241 shares
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59716000 USD
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74834952 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75524254 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73874904 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
915414000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
897607000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-695003000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-577530000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
274000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
599000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
220693000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
320684000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
432510000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
539433000 USD
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
44318000 USD
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
38684000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
86145000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
80098000 USD
CY2021Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
15000 USD
CY2020Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
15000000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
45000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
17805000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11263000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11655000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22609000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22403000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
55596000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
65339000 USD
us-gaap Operating Expenses
OperatingExpenses
108799000 USD
us-gaap Operating Expenses
OperatingExpenses
120306000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-55596000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-65339000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-108799000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-120306000 USD
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
141000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
898000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
334000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
2496000 USD
CY2021Q2 us-gaap Interest Expense
InterestExpense
4834000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
2491000 USD
us-gaap Interest Expense
InterestExpense
9614000 USD
us-gaap Interest Expense
InterestExpense
3198000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
457000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
62000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
606000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
64000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4236000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1531000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8674000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-638000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-59832000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-66870000 USD
us-gaap Net Income Loss
NetIncomeLoss
-117473000 USD
us-gaap Net Income Loss
NetIncomeLoss
-120944000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
162000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
78000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-210000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-46000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
994000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-115000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
318000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
116000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1072000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-325000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
309000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65798000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117798000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-120635000 USD
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74672882 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74672882 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66599915 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66599915 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74384805 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74384805 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64245119 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64245119 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
320684000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8708000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
759000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-57641000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-441000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
272084000 USD
CY2021Q2 goss Stock Issued During Period Value Vesting Of Restricted Stock
StockIssuedDuringPeriodValueVestingOfRestrictedStock
0 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
271000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8054000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-59832000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
116000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
220693000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
352485000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8244000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
556000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-54074000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-763000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
306463000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
117094000 USD
CY2020Q2 goss Equity Component Of Convertible Note Issuance
EquityComponentOfConvertibleNoteIssuance
53635000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
109000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8900000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-66870000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1072000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
420324000 USD
us-gaap Profit Loss
ProfitLoss
-117473000 USD
us-gaap Profit Loss
ProfitLoss
-120944000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
842000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
679000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
16762000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
17144000 USD
goss In Process Research And Development Expenses
InProcessResearchAndDevelopmentExpenses
45000 USD
goss In Process Research And Development Expenses
InProcessResearchAndDevelopmentExpenses
17805000 USD
goss Amortization Of Operating Lease Right Of Use Assets
AmortizationOfOperatingLeaseRightOfUseAssets
1729000 USD
goss Amortization Of Operating Lease Right Of Use Assets
AmortizationOfOperatingLeaseRightOfUseAssets
1203000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3284000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
823000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-115000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
33000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
253000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1373000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
548000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
43000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-932000 USD
goss Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1778000 USD
goss Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
715000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6631000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-727000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-342000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-982000 USD
goss Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
2775000 USD
goss Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-6103000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4258000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2975000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-106346000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-94694000 USD
goss Payments For Proceeds From Research And Development Asset Acquisitions
PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions
45000 USD
goss Payments For Proceeds From Research And Development Asset Acquisitions
PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions
17805000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
49923000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
73777000 USD
goss Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
12800000 USD
goss Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
143304000 USD
goss Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0 USD
goss Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
83515000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
940000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
954000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38108000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
134283000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117094000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
193596000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
759000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
556000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
286000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
154000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1045000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
311400000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-192000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-143601000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
350973000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
486620000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135089000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
343019000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
486062000 USD
us-gaap Interest Paid Net
InterestPaidNet
6365000 USD
us-gaap Interest Paid Net
InterestPaidNet
1243000 USD
goss Right Of Use Assets Obtained In Exchange For Lease Liabilities
RightOfUseAssetsObtainedInExchangeForLeaseLiabilities
0 USD
goss Right Of Use Assets Obtained In Exchange For Lease Liabilities
RightOfUseAssetsObtainedInExchangeForLeaseLiabilities
1192000 USD
goss Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax
NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax
-115000 USD
goss Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax
NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax
318000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
57000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-695000000.0 USD
goss Funds Raised Through Preferred Equity Financing Convertible Note Financings And Completed Initial Public Offering
FundsRaisedThroughPreferredEquityFinancingConvertibleNoteFinancingsAndCompletedInitialPublicOffering
942000000.0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the allocation of the 2027 Notes into liability and equity components and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9097000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8157000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3465000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2623000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5632000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5534000 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
63466000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8695000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12194000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3403000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3633000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2074000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2823000 USD
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1058000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1094000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
621000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
742000 USD
CY2021Q2 goss Accrued In Process Research And Development
AccruedInProcessResearchAndDevelopment
30000 USD
CY2020Q4 goss Accrued In Process Research And Development
AccruedInProcessResearchAndDevelopment
225000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15881000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20711000 USD
CY2021Q2 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0 USD
CY2020Q4 us-gaap Fair Value Equity Level2 To Level1 Transfers Amount
FairValueEquityLevel2ToLevel1TransfersAmount
0 USD
CY2020Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0 USD
CY2021Q2 us-gaap Fair Value Equity Level2 To Level1 Transfers Amount
FairValueEquityLevel2ToLevel1TransfersAmount
0 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
63404000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
62000 USD
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
63466000 USD
CY2021Q2 goss Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
0 USD
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
63466000 USD
CY2018Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
20000000.0 USD
CY2021Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
15000 USD
CY2020Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
15000000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
45000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
17805000 USD
goss Common Stock Voting Rights Number Of Votes Per Share
CommonStockVotingRightsNumberOfVotesPerShare
1 vote
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9433963 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
13.25
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117100000 USD
CY2021Q2 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
1153292 shares
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
1649348 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9401082 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.42
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10182000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2591751 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.70
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
109643 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1447260 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.71
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10435930 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6887000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
4431654 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
12.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5333000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.15
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8054000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8900000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16762000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17144000 USD
CY2019Q4 goss Option To Extend Contract Exercise Period
OptionToExtendContractExercisePeriod
P9M
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
0 USD
us-gaap Sublease Income
SubleaseIncome
0 USD
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1038000 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
817000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
2076000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1570000 USD
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000 USD
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
16000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
21000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
38000 USD
CY2021Q2 us-gaap Lease Cost
LeaseCost
1050000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
833000 USD
us-gaap Lease Cost
LeaseCost
2097000 USD
us-gaap Lease Cost
LeaseCost
1608000 USD
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1100000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
2100000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
800000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1500000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2146000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3579000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2063000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2123000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
387000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
397000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10695000 USD
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1127000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9568000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3403000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6165000 USD
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9568000 USD
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
2200000 USD
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000 USD

Files In Submission

Name View Source Status
0001728117-21-000087-index-headers.html Edgar Link pending
0001728117-21-000087-index.html Edgar Link pending
0001728117-21-000087.txt Edgar Link pending
0001728117-21-000087-xbrl.zip Edgar Link pending
exhibit101.htm Edgar Link pending
exhibit102.htm Edgar Link pending
exhibit103.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
goss-20210630.htm Edgar Link pending
goss-20210630.xsd Edgar Link pending
goss-20210630x10qxexx311.htm Edgar Link pending
goss-20210630x10qxexx312.htm Edgar Link pending
goss-20210630x10qxexx321.htm Edgar Link pending
goss-20210630x10qxexx322.htm Edgar Link pending
goss-20210630_cal.xml Edgar Link unprocessable
goss-20210630_def.xml Edgar Link unprocessable
goss-20210630_htm.xml Edgar Link completed
goss-20210630_lab.xml Edgar Link unprocessable
goss-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending